Wird geladen...
Targeting CREB in Cancer Therapy: A Key Candidate or One of Many? An Update
SIMPLE SUMMARY: Only 5% of all drug-related targets currently move from preclinical to clinical in cancer, and just some of them achieve patient’s bedside. Among others, intratumor heterogeneity and preclinical cancer model limitations actually represent the main reasons for this failure. Cyclic-AMP...
Gespeichert in:
| Veröffentlicht in: | Cancers (Basel) |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
MDPI
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7693618/ https://ncbi.nlm.nih.gov/pubmed/33126560 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12113166 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|